[EN] MACROCYCLIC AZOLOPYRIDINE DERIVATIVES AS EED AND PRC2 MODULATORS [FR] DÉRIVÉS D'AZOLOPYRIDINE MACROCYCLIQUES UTILISÉS EN TANT QUE MODULATEURS EED ET PRC2
摘要:
本发明涉及用于治疗与Embryonic Ectoderm Development (EED)和/或Polycomb Repressive Complex 2 (PRC2)相关的疾病和障碍的调节剂,是式(I)所示的宏环唑啉衍生物及其组合物,或其药用可接受的盐、前药、溶剂化物、水合物、对映体、异构体或互变异构体,其中X1、X2、X3、A1、A2、Y、R1、R2、R3和R4如本文所述。
Synthesis of 4-amino-5-fluoropyrimidines and 5-amino-4-fluoropyrazoles from a β-fluoroenolate salt
作者:Tobias Lucas、Jule-Philipp Dietz、Till Opatz
DOI:10.3762/bjoc.16.41
日期:——
A synthesis of fluorinated pyrimidines under mild conditions from amidine hydrochlorides and the recently described potassium 2-cyano-2-fluoroethenolate was developed. A broad substrate scope was tested and mostly excellent yields were obtained. The synthesis of fluorinated aminopyrazoles from the same fluorinated precursor could be demonstrated but proceeded with lower efficiency.
The present invention relates to a compound of Formula (I):
or
a pharmaceutically acceptable salt thereof, corresponding pharmaceutical compositions, compound preparation and treatment methods directed to bacterial infections and inhibition of bacterial peptide deformylase (PDF) activity.
[EN] COMPOUNDS, COMPOSITIONS AND METHODS<br/>[FR] COMPOSÉS, COMPOSITIONS ET MÉTHODES
申请人:DENALI THERAPEUTICS INC
公开号:WO2022006433A1
公开(公告)日:2022-01-06
The present disclosure relates generally to small molecule modulators of NLR Family Pyrin Domain Containing 3 (NLRP3), or a pharmaceutically acceptable salt, isotopically enriched analog, stereoisomer, mixture of stereoisomers, or prodrug thereof, methods of making and intermediates thereof, and methods of using thereof.
本公开涉及一般性地小分子调节剂NLR Family Pyrin Domain Containing 3 (NLRP3),或其药用盐、同位素富集的类似物、立体异构体、立体异构体混合物或前药,以及制备方法和中间体的方法,以及使用方法。
2,4-Pyrimidinediamine compounds and their uses
申请人:Singh Rajinder
公开号:US20050209230A1
公开(公告)日:2005-09-22
The present invention provides 2,4-pyrimidinediamine compounds that inhibit the IgE and/or IgG receptor signaling cascades that lead to the release of chemical mediators, intermediates and methods of synthesizing the compounds and methods of using the compounds in a variety of contexts, including in the treatment and prevention of diseases characterized by, caused by or associated with the release of chemical mediators via degranulation and other processes effected by activation of the IgE and/or IgG receptor signaling cascades.
본 발명은 NLRP3 저해제로서 화학식 1로 표시되는 화합물, 이의 입체 이성질체 또는 이의 약학적으로 허용 가능한 염 및 이를 유효성분으로 포함하는 약학적 조성물에 관한 것으로, 상기 화합물, 이의 입체 이성질체 또는 이의 약학적으로 허용 가능한 염 및 이를 유효성분으로 포함하는 약학적 조성물은 NLRP3 활성 관련 질환의 예방 또는 치료에 유용하게 사용될 수 있다. [화학식 1]